Dr Reddy Labs receives EIR for Srikakulam plant

The US drug regulator has issued Establishment Inspection Report to Dr. Reddy's Laboratories' active pharmaceutical ingredient (API) plant in Srikakulam (SEZ), Andhra Pradesh.

The audit of the plant was completed by the US Food and Drug Administration (USFDA) in June 2018 with no observations.

On the other hand, Dr. Reddy's initiated a voluntary recall of Atorvastatin Calcium tablets in the US market. The cholesterol-lowering tablets was called back through a Class-3 recall after noticing anomalies during out of specifications (OOS) investigations. More than 2,000 bottles of 40 mg tablets were recalled following Failed impurities/degradation specifications -OOS.

Reacting to this mix of positive and negative news, the stock of Dr. Reddy's Lab was quoting Rs. 2,452.45 per share, down by Rs. 12.15 or 0.49 per cent at 11:26 hours on Friday. While the BSE Sensex was at 38,297.46, down 39.30 points or 0.10 per cent.